Charles Schwab Investment Management Inc Candel Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 83,880 shares of CADL stock, worth $457,146. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,880
Previous 52,190
60.72%
Holding current value
$457,146
Previous $453,000
4.42%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CADL
# of Institutions
88Shares Held
15.2MCall Options Held
536KPut Options Held
335K-
Baker Bros. Advisors LP New York, NY2.44MShares$13.3 Million0.16% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.15MShares$11.7 Million8.46% of portfolio
-
Northpond Ventures, LLC1.94MShares$10.5 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.74MShares$9.46 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA881KShares$4.8 Million0.41% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $157M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...